Tuftsin-phosphorylcholine attenuate experimental autoimmune encephalomyelitis

J Neuroimmunol. 2019 Dec 15;337:577070. doi: 10.1016/j.jneuroim.2019.577070. Epub 2019 Oct 24.

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) which carries a significant burden of morbidity and mortality. Herein we examine the effects of acute treatment with tuftsin-phosphorylcholine (TPC), a novel immune-modulating helminth derived compound, on a murine model of MS. Experimental autoimmune encephalomyelitis (EAE) mice received acute treatment with TPC showed an improved clinical score and significantly less signs of inflammation and demyelination in CNS tissue compared with vehicle treated EAE mice. Our findings suggest that TPC may provide a beneficial clinical effect in EAE and may therefore have a potential value for ameliorating clinical manifestations and delaying disease progression in MS.

Keywords: Autoimmunity; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Tuftsin-phosphorylcholine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Drug Combinations
  • Encephalomyelitis, Autoimmune, Experimental / immunology
  • Encephalomyelitis, Autoimmune, Experimental / pathology*
  • Encephalomyelitis, Autoimmune, Experimental / prevention & control*
  • Female
  • Inflammation Mediators / antagonists & inhibitors*
  • Inflammation Mediators / immunology
  • Mice
  • Mice, Inbred C57BL
  • Phosphorylcholine / analogs & derivatives*
  • Phosphorylcholine / therapeutic use
  • Tuftsin / therapeutic use*

Substances

  • Drug Combinations
  • Inflammation Mediators
  • tuftsin-phosphorylcholine
  • Phosphorylcholine
  • Tuftsin